Single Dose

Dr. Davin Rautiola is a pharmaceutical scientist, engineer, and biotechnology executive specializing in translational medicine. He founded Single Dose Therapeutics to advance transformative neuroadaptive drugs like SD-A001 as interventional pharmacotherapies for refractory psychiatric conditions and resilience enhancing agents to strengthen adaptive capacity for improved mental health. This work stems from decades of interest in psychoplastogens, a class of compounds with roots in traditional medicine that have been used throughout human history to facilitate insight into maladaptive behaviors and thought patterns. Dr. Rautiola has dedicated his career to bridging the gap between scientific discovery and real world medical impact. At Gilead Sciences, Dr. Rautiola was a Drug Product Lead for some of the company's most complex programs, developing long-acting injectable and inhalation drug products for therapeutic areas such as virology and fibrotic diseases. He received his MEng in pharmaceutical engineering from the University of Michigan and PhD in pharmaceutics from the University of Minnesota. Dr. Rautiola brings broad leadership experience and multidisciplinary expertise that spans the drug development continuum, from discovery through commercialization.

Dr. Jason Carl Rosenberg serves as Chief Operating Officer of Single Dose Therapeutics. He brings more than 13 years of leadership experience across life sciences, neurotechnology, and health technology, with expertise in strategic partnerships, contracting, vendor management, and the operational execution of complex development programs. Prior to joining Single Dose Therapeutics, Dr. Rosenberg helped scale a neurorehabilitation clinical platform at MindMaze Therapeutics from 10 to 250 sites across the U.S. and Europe, built and managed multi-vendor partnerships spanning six continents at Tessa Therapeutics, and led the development of more than 275 agreements representing over $20 million in commercial value. He has also secured more than $8 million in research and grant funding. Dr. Rosenberg received his PhD in Music, Neuroscience from the University of California, San Diego. He has testified before Congress on brain health and delivered two TEDx Talks.

Dr. Michael Ostacher is Professor of Psychiatry and Behavioral Sciences at Stanford University. He is the Site Director for the Addiction Medicine Fellowship at the VA Palo Alto Health Care System, where he also serves as the Medical Director of the Pharmacology of Addiction Recovery Clinic, the Director of the Bipolar and Depression Research Program and the Co-Director of the VA/Stanford Exploratory Therapeutics Lab, the Director of Advanced Fellowship Training in Mental Illness Research and Treatment for MDs for the VISN 21 MIRECC, and the Site Director at the VA Palo Alto for Advanced Fellowship Training for Stanford. A graduate of Vanderbilt University School of Medicine, the Harvard School of Public Health, and Harvard Medical School, he completed his training at The Cambridge Health Alliance at Harvard Medical School in Adult Psychiatry, Public Psychiatry, and Geriatric Psychiatry, and is currently board certified in Psychiatry, Addiction Psychiatry, and Addiction Medicine.

Dr. Francis Filloux is a professor of pediatric neurology at the University of Utah and practicing pediatric neurologist with over 35 years of experience in the field. His work has sought to advance understanding and treatment options for children with various neurological conditions, including neurogenetic disorders such as Pallister-Killian syndrome and neurobehavioral disorders such as Tourette Syndrome. Dr. Filloux was involved in the clinical development of cannabidiol, leading to FDA approval of Epidiolex as a highly effective anti-seizure medication. He is currently an epilepsy specialist within the University of Utah’s Division of Pediatric Neurology, providing expert consultation for children with all forms of epilepsy and interpreting standard scalp EEGs as well as intracerebral recordings, including stereo-EEGs. Dr. Filloux received his MD from the University of California Los Angeles and completed his residency in pediatric neurology at the University of Utah School of Medicine.

Dr. Shichang Miao is a seasoned drug developer with over 25 years of experience in drug discovery and small-molecule development, having advanced 13 candidates into the clinic across Tularik, ChemoCentryx, and Amgen. He is Co-Managing Partner of Rivermount Fund which specializes in early-stage investment in healthcare startup companies. He serves on the advisory committee of the Stanford SPARK Translational Research Program and the Bio Committee of Life Science Angels, a prominent angel investment group focusing on healthcare startups. He is an active contributor to biotech professional societies, and is the Founder and President of the Pharmaceutical & BioScience Society (PBSS). He obtained his PhD in organic chemistry and postdoctoral training in biochemistry at the University of British Columbia in Vancouver.

Sharon Clarke brings more than 20 years of industry experience in building and leading commercial organizations in highly competitive, cost-sensitive markets. President and General Manager of MEDA US, Ms. Clarke led the US division to increased revenue and record profitability while launching four products in the highly competitive respiratory and pain therapeutic markets. As Chief Commercial Officer at Zensights, she advises emerging biotechnology companies and established global pharmaceutical companies who were looking to optimize organizational effectiveness and develop leadership at all levels of their organizations. Ms. Clarke has led Commercial Operations for several pharmaceutical companies, building their commercial teams and operational infrastructure, and leading launches of both pain and neurology products. She is a member of the Board of Trustees of East Tennessee State University, from which she was graduated magna cum laude with degrees in microbiology and chemistry.

Dr. Kevin Lanzo is a pharmacist, clinical scientist, and consultant specializing in researching the clinical effects of psychoactive medicines. In 5 years of working as a clinical scientist at Genentech, he developed Phase II & Phase III clinical trial programs in Ophthalmology, Multiple Sclerosis, and led the establishment of a program investigating psychedelics for mental health indications. Dr. Lanzo founded Pharmaka Clinical Consulting, where he now assists companies developing clinical development strategies for novel psychedelics & psychoplastogens. He completed a postdoctoral pharmaceutical industry fellowship with Rutgers University, serves as Co-Founder and Board Member at the Psychedelic Pharmacists Association, and is Executive-In-Residence at Lionheart Ventures.